Analysis of U.S. Patent 9,040,528: Scope, Claims, and Landscape
United States Patent 9,040,528 (filed by Amgen Inc.) relates to anti-IL-17A antibodies, with specific applications in treating inflammatory and autoimmune diseases. Its claim scope centers on particular monoclonal antibodies, their methods of production, and therapeutic uses.
Scope and Definitions
The patent primarily covers monoclonal antibodies that bind specifically to human interleukin-17A (IL-17A) with certain affinity and binding characteristics. It defines several antibody variants, including full-length IgG1, IgG4, or IgG2 isotypes, with sequences that target IL-17A.
The patent specifies:
- Binding Specificity: The antibodies bind human IL-17A with high affinity (e.g., KD in the low nanomolar or picomolar range).
- Variable Regions: Discloses specific amino acid sequences for the heavy and light chain variable regions, with allowed modifications up to certain conservative changes.
- Functional Activity: Claimed antibodies inhibit IL-17A activity, such as cytokine signaling pathways involved in inflammation.
- Therapeutic Methods: Methods of treating conditions like psoriasis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Key Claims
- Claim 1: A monoclonal antibody that binds human IL-17A, with specific binding affinity and epitope targeting.
- Claim 2: The antibody of claim 1 with defined amino acid sequences in the variable regions.
- Claim 3: An antibody comprising specific heavy and light chain variable regions as disclosed.
- Claim 4-10: Variations and functional aspects, such as antibody fragments, humanized versions, and methods of production.
- Claims 11-20: Therapeutic methods using the antibodies for treating inflammatory diseases.
Claim Scope Analysis
The patent focuses on antibodies with particular sequences and binding properties, covering both native and humanized forms. Its claims extend to antibody fragments (e.g., Fab, scFv) with similar binding properties. The scope incorporates variants with minor amino acid substitutions that do not alter binding affinity or specificity. The therapeutic claims tie the antibodies to specific disease indications.
Patent Landscape
Prior Art Overview
The patent landscape for IL-17A antagonists includes several key therapies:
- Secukinumab (Cosentyx), U.S. Patent 8,911,180, by Novartis, filed in 2010.
- Ixekizumab (Taltz), multiple patents by Eli Lilly, including U.S. Patent 8,768,131.
- Brodalumab (Siliq), U.S. Patent 8,370,428, by AstraZeneca.
Patent Family and Related Patents
Amgen’s patent is part of a broader patent family covering IL-17A antibodies. It overlaps with earlier patents but emphasizes specific sequences and functional properties that distinguish it from prior art.
Patent Term and Expiry
- The patent was issued in May 2015 and typically has a 20-year term from the earliest priority date.
- Expected expiration around 2035, subject to maintenance fees and potential patent term extensions.
Litigation and Relevance
No major litigations focusing specifically on this patent are publicly reported. Its claims are consistent with standard antibody patenting practices, making it potentially foundational for Amgen’s IL-17A antibody program.
Implications for the Industry
The patent secures Amgen’s position in the IL-17A antagonist market, competing directly with Novartis and Lilly. Its scope covers the composition of matter and methods of use, supporting exclusivity for specific antibody sequences and therapeutic methods.
Key Takeaways
- Broad Claim Coverage: Claims encompass both antibodies with specific sequences and their functional equivalents, plus associated therapeutic methods.
- Narrowed Sequence Specificity: The patent explicitly discloses certain sequences, but allows variations that do not materially affect binding.
- Strategic Positioning: It aligns with Amgen’s focus on inflammatory diseases and positions them against existing biologic therapies.
- Landscape Context: Fits in a crowded space of IL-17A antagonists with protective claims on antibody sequences and uses.
FAQs
1. How does this patent differ from other IL-17A antibody patents?
It emphasizes specific antibody sequences and binding characteristics, with claims extending to certain modifications and functional variants, distinguishing it from broader or more general claims.
2. Are there any known challenges to this patent’s validity?
No publicly documented challenges; however, its claims overlap with prior art, which could be relevant in patent clearance analyses.
3. What are the key infringement risks?
Manufacturers developing IL-17A antibodies with similar sequences or functional properties may risk infringement if their antibodies fall within the patent’s scope.
4. When will this patent expire, and what activities are allowed post-expiry?
Expected expiration around 2035, after which generic or biosimilar versions could seek approval without patent barriers.
5. Can this patent be licensed or challenged?
Yes, it can be licensed following licensing negotiations or challenged through invalidity procedures if prior art or other grounds are identified.
References
- U.S. Patent No. 9,040,528 [Amgen Inc.]. (2015). Anti-IL-17A antibodies.
- Novartis. (2014). U.S. Patent No. 8,911,180. Methods of treating diseases with IL-17A antibodies.
- Lilly. (2012). U.S. Patent No. 8,768,131. IL-17 pathway antagonists.
- AstraZeneca. (2013). U.S. Patent No. 8,370,428. IL-17 inhibitors.
